- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00336024
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue vs. the Same Therapy Without Methotrexate
Study Overview
Status
Conditions
Intervention / Treatment
- Other: Laboratory Biomarker Analysis
- Drug: Carboplatin
- Drug: Etoposide
- Other: Quality-of-Life Assessment
- Drug: Cisplatin
- Drug: Cyclophosphamide
- Drug: Vincristine Sulfate
- Drug: Methotrexate
- Biological: Filgrastim
- Drug: Thiotepa
- Procedure: Autologous Hematopoietic Stem Cell Transplantation
- Drug: Leucovorin Calcium
Detailed Description
PRIMARY OBJECTIVES:
I. To determine if treatment of infants with high risk primitive neuroectodermal tumors (PNET) central nervous system (CNS) tumors with intensive chemotherapy plus high-dose methotrexate and peripheral blood stem cell rescue results in a higher complete response rate then the same regimen without methotrexate.
SECONDARY OBJECTIVES:
I. To determine whether biologic characterization of these tumors will refine therapeutic stratification separating atypical teratoid rhabdoid tumors (AT/RT) from primitive neuroectodermal tumors (PNETs) and possibly identifying other markers of value for stratification within the group of PNETs.
II. To determine if event free survival (EFS) and patterns of failure differ between the methotrexate arm versus the arm without methotrexate.
III. To compare the acute, chronic and late effects of these two very intensive regimens, especially as to the tolerance of the same consolidation regimen following the differing induction regimens.
IV. To compare the gastrointestinal and nutritional toxicities of these intense regimens.
V. To describe and compare the quality of life outcomes and neuropsychological effects of these intense systemic therapies.
OUTLINE: Patients are randomized to 1 of 2 treatment arms
INDUCTION THERAPY:
ARM I: Patients receive vincristine IV over 1 minute on days 1, 8, and 15; etoposide IV over 1 hour on days 1-3; cyclophosphamide IV over 1 hour on days 1 and 2; cisplatin IV over 6 hours on day 3; and filgrastim (G-CSF) IV or subcutaneously (SC) beginning on day 4 and continuing until blood counts recover. Treatment repeats every 3 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive vincristine IV over 1 minute on days 1, 8, and 15; high-dose methotrexate IV over 4 hours on day 1; and leucovorin calcium IV or orally (PO) every 6 hours beginning on day 2 and continuing until methotrexate levels are in a safe range. Once methotrexate levels are in a safe range, patients then receive etoposide IV over 1 hour on approximately days 4, 5, and 6, cyclophosphamide IV over 1 hour on approximately days 4 and 5, and cisplatin IV over 6 hours on approximately day 6. Patients also receive G-CSF IV or SC beginning 24 hours after the completion of chemotherapy and continuing until blood counts recover. Treatment repeats every 3 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
In both arms, patients with stable disease or partial response after induction therapy proceed to second-look surgery followed by consolidation therapy. Patients with a complete response after induction therapy proceed directly to consolidation therapy.
CONSOLIDATION THERAPY: Beginning no more than 6 weeks after completion of induction therapy, patients receive consolidation therapy comprising carboplatin IV over 2 hours and thiotepa IV over 2 hours on days 1 and 2 and G-CSF IV or SC beginning on day 5 and continuing until blood counts recover. Patients also receive autologous peripheral blood stem cells (PBSC) IV on day 4. Treatment repeats every 4 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
After completion of study therapy, patients are followed up periodically for 4 years and then annually thereafter.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
New South Wales
-
Randwick, New South Wales, Australia, 2031
- Sydney Children's Hospital
-
Westmead, New South Wales, Australia, 2145
- The Children's Hospital at Westmead
-
-
Victoria
-
Parkville, Victoria, Australia, 3052
- Royal Children's Hospital
-
-
Western Australia
-
Perth, Western Australia, Australia, 6008
- Princess Margaret Hospital for Children
-
-
-
-
-
Quebec, Canada, G1V 4G2
- Centre Hospitalier Universitaire de Quebec
-
-
Alberta
-
Calgary, Alberta, Canada, T3B 6A8
- Alberta Children's Hospital
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3V4
- British Columbia Children's Hospital
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- CancerCare Manitoba
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3K 6R8
- IWK Health Centre
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3Z5
- McMaster Children's Hospital at Hamilton Health Sciences
-
Kingston, Ontario, Canada, K7L 2V7
- Kingston Health Sciences Centre
-
Ottawa, Ontario, Canada, K1H 8L1
- Children's Hospital of Eastern Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- Hospital for Sick Children
-
-
Quebec
-
Montreal, Quebec, Canada, H3H 1P3
- The Montreal Children's Hospital of the MUHC
-
Montreal, Quebec, Canada, H3T 1C5
- Centre Hospitalier Universitaire Sainte-Justine
-
-
-
-
-
San Juan, Puerto Rico, 00912
- San Jorge Children's Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- University of Alabama at Birmingham Cancer Center
-
Birmingham, Alabama, United States, 35233
- Children's Hospital of Alabama
-
-
Arizona
-
Phoenix, Arizona, United States, 85016
- Phoenix Childrens Hospital
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- University of Arkansas for Medical Sciences
-
Little Rock, Arkansas, United States, 72202-3591
- Arkansas Children's Hospital
-
-
California
-
Downey, California, United States, 90242
- Kaiser Permanente Downey Medical Center
-
Loma Linda, California, United States, 92354
- Loma Linda University Medical Center
-
Long Beach, California, United States, 90806
- Miller Children's and Women's Hospital Long Beach
-
Los Angeles, California, United States, 90027
- Children's Hospital Los Angeles
-
Los Angeles, California, United States, 90048
- Cedars Sinai Medical Center
-
Madera, California, United States, 93636
- Valley Children's Hospital
-
Orange, California, United States, 92868
- Children's Hospital of Orange County
-
Sacramento, California, United States, 95816
- Sutter Medical Center Sacramento
-
Sacramento, California, United States, 95817
- University of California Davis Comprehensive Cancer Center
-
San Diego, California, United States, 92123
- Rady Children's Hospital - San Diego
-
San Francisco, California, United States, 94143
- UCSF Medical Center-Parnassus
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Children's Hospital Colorado
-
-
Connecticut
-
Hartford, Connecticut, United States, 06106
- Connecticut Children's Medical Center
-
-
Delaware
-
Wilmington, Delaware, United States, 19803
- Alfred I duPont Hospital for Children
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Children's National Medical Center
-
-
Florida
-
Fort Lauderdale, Florida, United States, 33316
- Broward Health Medical Center
-
Fort Myers, Florida, United States, 33908
- Golisano Children's Hospital of Southwest Florida
-
Fort Myers, Florida, United States, 33901
- Lee Memorial Health System
-
Gainesville, Florida, United States, 32610
- University of Florida Health Science Center - Gainesville
-
Hollywood, Florida, United States, 33021
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Jacksonville, Florida, United States, 32207
- Nemours Children's Clinic-Jacksonville
-
Miami, Florida, United States, 33155
- Nicklaus Children's Hospital
-
Miami, Florida, United States, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Orlando, Florida, United States, 32806
- Orlando Health Cancer Institute
-
Orlando, Florida, United States, 32806
- Nemours Children's Clinic - Orlando
-
Orlando, Florida, United States, 32827
- Nemours Children's Hospital
-
Orlando, Florida, United States, 32803
- AdventHealth Orlando
-
Orlando, Florida, United States, 32806
- Arnold Palmer Hospital for Children
-
Pensacola, Florida, United States, 32504
- Nemours Children's Clinic - Pensacola
-
Saint Petersburg, Florida, United States, 33701
- Johns Hopkins All Children's Hospital
-
Tampa, Florida, United States, 33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
West Palm Beach, Florida, United States, 33407
- Saint Mary's Hospital
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Children's Healthcare of Atlanta - Egleston
-
Savannah, Georgia, United States, 31404
- Memorial Health University Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96813
- University of Hawaii Cancer Center
-
-
Idaho
-
Boise, Idaho, United States, 83712
- Saint Luke's Cancer Institute - Boise
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Lurie Children's Hospital-Chicago
-
Maywood, Illinois, United States, 60153
- Loyola University Medical Center
-
Oak Lawn, Illinois, United States, 60453
- Advocate Children's Hospital-Oak Lawn
-
-
Indiana
-
Indianapolis, Indiana, United States, 46260
- Ascension Saint Vincent Indianapolis Hospital
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- University of Kentucky/Markey Cancer Center
-
Louisville, Kentucky, United States, 40202
- Norton Children's Hospital
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Tulane University Health Sciences Center
-
-
Maine
-
Bangor, Maine, United States, 04401
- Eastern Maine Medical Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Bethesda, Maryland, United States, 20889-5600
- Walter Reed National Military Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, United States, 02111
- Tufts Children's Hospital
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- C S Mott Children's Hospital
-
East Lansing, Michigan, United States, 48824-7016
- Michigan State University Clinical Center
-
Grand Rapids, Michigan, United States, 49503
- Helen DeVos Children's Hospital at Spectrum Health
-
Kalamazoo, Michigan, United States, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, United States, 49008
- Kalamazoo Center for Medical Studies
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55404
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota/Masonic Cancer Center
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic in Rochester
-
-
Mississippi
-
Jackson, Mississippi, United States, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Kansas City, Missouri, United States, 64108
- Children's Mercy Hospitals and Clinics
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
Saint Louis, Missouri, United States, 63141
- Mercy Hospital Saint Louis
-
Saint Louis, Missouri, United States, 63104
- Cardinal Glennon Children's Medical Center
-
-
Nevada
-
Las Vegas, Nevada, United States, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas, Nevada, United States, 89169
- Nevada Cancer Research Foundation NCORP
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Hackensack University Medical Center
-
Morristown, New Jersey, United States, 07960
- Morristown Medical Center
-
New Brunswick, New Jersey, United States, 08903
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Newark, New Jersey, United States, 07112
- Newark Beth Israel Medical Center
-
Paterson, New Jersey, United States, 07503
- Saint Joseph's Regional Medical Center
-
Summit, New Jersey, United States, 07902
- Overlook Hospital
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87102
- University of New Mexico Cancer Center
-
-
New York
-
Bronx, New York, United States, 10467
- Montefiore Medical Center - Moses Campus
-
Buffalo, New York, United States, 14263
- Roswell Park Cancer Institute
-
Mineola, New York, United States, 11501
- NYU Winthrop Hospital
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, United States, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, United States, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, United States, 14642
- University of Rochester
-
Stony Brook, New York, United States, 11794
- Stony Brook University Medical Center
-
Valhalla, New York, United States, 10595
- New York Medical College
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Charlotte, North Carolina, United States, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
Charlotte, North Carolina, United States, 28204
- Novant Health Presbyterian Medical Center
-
-
North Dakota
-
Fargo, North Dakota, United States, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, United States, 44106
- Rainbow Babies and Childrens Hospital
-
Columbus, Ohio, United States, 43205
- Nationwide Children's Hospital
-
Dayton, Ohio, United States, 45404
- Dayton Children's Hospital
-
Toledo, Ohio, United States, 43606
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
Toledo, Ohio, United States, 43608
- Mercy Children's Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health and Science University
-
Portland, Oregon, United States, 97227
- Legacy Emanuel Children's Hospital
-
Portland, Oregon, United States, 97227
- Legacy Emanuel Hospital and Health Center
-
-
Pennsylvania
-
Danville, Pennsylvania, United States, 17822
- Geisinger Medical Center
-
Philadelphia, Pennsylvania, United States, 19104
- Children's Hospital of Philadelphia
-
Philadelphia, Pennsylvania, United States, 19134
- Saint Christopher's Hospital for Children
-
Pittsburgh, Pennsylvania, United States, 15224
- Children's Hospital of Pittsburgh of UPMC
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
Columbia, South Carolina, United States, 29203
- Prisma Health Richland Hospital
-
Greenville, South Carolina, United States, 29605
- BI-LO Charities Children's Cancer Center
-
Greenville, South Carolina, United States, 29605
- Greenville Cancer Treatment Center
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37916
- East Tennessee Childrens Hospital
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Amarillo, Texas, United States, 79106
- Texas Tech University Health Sciences Center-Amarillo
-
Corpus Christi, Texas, United States, 78411
- Driscoll Children's Hospital
-
Dallas, Texas, United States, 75230
- Medical City Dallas Hospital
-
Fort Worth, Texas, United States, 76104
- Cook Children's Medical Center
-
Houston, Texas, United States, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Lubbock, Texas, United States, 79410
- Covenant Children's Hospital
-
San Antonio, Texas, United States, 78229
- University of Texas Health Science Center at San Antonio
-
San Antonio, Texas, United States, 78229
- Methodist Children's Hospital of South Texas
-
-
Utah
-
Salt Lake City, Utah, United States, 84113
- Primary Children's Hospital
-
-
Vermont
-
Burlington, Vermont, United States, 05405
- University of Vermont and State Agricultural College
-
-
Virginia
-
Falls Church, Virginia, United States, 22042
- Inova Fairfax Hospital
-
Portsmouth, Virginia, United States, 23708-2197
- Naval Medical Center - Portsmouth
-
Richmond, Virginia, United States, 23298
- Virginia Commonwealth University/Massey Cancer Center
-
-
Washington
-
Seattle, Washington, United States, 98105
- Seattle Children's Hospital
-
Spokane, Washington, United States, 99204
- Providence Sacred Heart Medical Center and Children's Hospital
-
Tacoma, Washington, United States, 98405
- Mary Bridge Children's Hospital and Health Center
-
-
Wisconsin
-
Marshfield, Wisconsin, United States, 54449
- Marshfield Medical Center-Marshfield
-
Milwaukee, Wisconsin, United States, 53226
- Children's Hospital of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
High-risk medulloblastoma defined by any of the following:
- > 1.5 cm^2 residual disease for any medulloblastoma histology, or
- Lumbar cerebral spinal fluid (CSF) cytology positive for tumor cells by analysis of fluid collected either before definitive surgery or at least 10 days after definitive surgery unless contraindicated, or
- Magnetic resonance imaging (MRI) evidence of M2 or M3 metastatic disease, or
- M4 disease
- Supratentorial primitive neuroectodermal tumor (PNET) (any M-stage) will be eligible for study entry
- Children less than 8 months of age at the time of definitive surgery with or without measurable radiographic residual tumor with M0 stage medulloblastoma will be eligible for study entry
- Patients with anaplastic medulloblastoma are eligible regardless of M-stage or residual tumor
- Patients with M0 classic, non-desmoplastic medulloblastoma (R1) with radiographically measurable residual disease < 1.5 cm^2 are eligible
- Cranial MRI (with and without gadolinium) must be done pre-operatively; post-operatively, cranial MRI (with and without gadolinium) must be done, preferably within 48 hours of surgery; entire spinal MRI must be obtained either pre-operatively (with gadolinium) or post-operatively (at least 10 days following surgery) prior to study enrollment (with and without gadolinium); patients with MRI evidence of spinal disease are eligible for this study
- Evaluation of lumbar CSF cytology (cytospin preparation for microscopic evaluation) must be performed either pre-operatively or at least 10 days after definitive surgery unless contraindicated
- Patient must have a life expectancy > 8 weeks
- Patient must have received no prior radiation therapy or chemotherapy other than corticosteroids; corticosteroids are allowable for all patients
- Creatinine clearance or radioisotope glomerular filtration rate >= 60 mL/min
- Total bilirubin =< 1.5 x upper limit of normal (ULN) for age, and
- Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and serum glutamic pyruvic transaminase (SGPT) (alanine transaminase [ALT]) < 2 x ULN for age
- Shortening fraction >= 27% by echocardiogram, or
- Ejection fraction >= 47% by radionuclide angiogram
- No evidence of dyspnea at rest
- Pulse oximetry > 94% on room air
- Peripheral absolute neutrophil count (ANC) > 1,000/uL
- Platelet count > 100,000/uL (transfusion independent)
- Hemoglobin greater than 8 g/dL (may have received red blood cell [RBC] transfusions allowed)
- Hold trimethoprim/sulfamethoxazole (Bactrim) on the day of high-dose methotrexate (HDMTX) infusion and continue to hold until the methotrexate level is less than 0.1 micromolar (1 x 10-7 M)
- Avoid probenecid, penicillins, cephalosporins, aspirin, proton pump inhibitors and nonsteroidal anti-inflammatory drug (NSAIDS) on the day of methotrexate and continue until the methotrexate level is less than 0.1 micromolar (1 x 10-7 M) as renal excretion of methotrexate is inhibited by these agents
- Avoid IV contrast media, urinary acidifiers, phenytoin, and fosphenytoin on the day of methotrexate and until the methotrexate level is less than 0.1 micromolar (1 x 10-7 M)
- Concurrent use of enzyme inducing anticonvulsants (e.g. phenytoin, phenobarbital, and carbamazepine) should be avoided
- Clinically significant drug interactions have been reported when using vincristine with strong cytochrome P450 (CYP450) family 3 subfamily A member 4 (3A4) inhibitors and inducers; selected strong inhibitors of cytochrome P450 3A4 include azole antifungals, such as fluconazole, voriconazole, itraconazole, ketoconazole, and strong inducers include drugs such as rifampin, phenytoin, phenobarbitol, carbamazepine, and St. John's wort; the use of these drugs should be avoided with vincristine
- All patients and/or their parents or legal guardians must sign a written informed consent
- All institutional, Food and Drug administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm I (induction+consolidation chemotherapy, autologous PBSC)
Patients receive vincristine IV over 1 minute on days 1, 8, and 15; etoposide IV over 1 hour on days 1-3; cyclophosphamide IV over 1 hour on days 1 and 2; cisplatin IV over 6 hours on day 3. Treatment repeats every 3 weeks for 3 courses. Within 6 weeks after completion of induction therapy, patients receive consolidation therapy comprising carboplatin IV over 2 hours and thiotepa IV over 2 hours on days 1 and 2 and G-CSF IV or SC beginning on day 5 and continuing until blood counts recover. Patients also receive autologous PBSC IV on day 4. Treatment repeats every 4 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. |
Correlative studies
Given IV
Other Names:
Given IV
Other Names:
Ancillary studies
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV or SC
Other Names:
Given IV
Other Names:
Undergo autologous PBSC resuce
Other Names:
|
Experimental: Arm II (induction+consolidation chemotherapy, autologous PBSC)
Patients receive vincristine IV over 1 minute on days 1, 8, and 15; high-dose methotrexate IV over 4 hours on day 1; and leucovorin calcium IV or PO every 6 hours beginning on day 2 and continuing until methotrexate levels are in a safe range. Patients then receive etoposide IV over 1 hour on approximately days 4, 5, and 6, cyclophosphamide IV over 1 hour on approximately days 4 and 5, and cisplatin IV over 6 hours on approximately day 6. Treatment repeats every 3 weeks for 3 courses. Within 6 weeks after completion of induction therapy, patients receive consolidation therapy comprising carboplatin IV over 2 hours and thiotepa IV over 2 hours on days 1 and 2 and G-CSF IV or SC beginning on day 5 and continuing until blood counts recover. Patients also receive autologous PBSC IV on day 4. Treatment repeats every 4 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. |
Correlative studies
Given IV
Other Names:
Given IV
Other Names:
Ancillary studies
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV or SC
Other Names:
Given IV
Other Names:
Undergo autologous PBSC resuce
Other Names:
Given IV or orally
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients Who Have Either a Complete Response (CR) Rate or No Complete Response Rate
Time Frame: At the end of consolidation treatment
|
At the end of consolidation, the number of evaluable patients treated with intensive chemotherapy with methotrexate who achieved CR or not will be compared to those who achieved CR or not after treated with the same intensive chemotherapy without methotrexate.
The CR rates between these two groups will be compared at a significance level of 0.1 using one-sided Chi-square test.
Complete Response (CR) requires: CR for target lesions: disappearance of all target lesions, CR for non-target lesions: disappearance of all non-target lesions and no new lesions.
No CR is any response not fitting the definition of CR.
|
At the end of consolidation treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Molecular Sub-types of MB, CNS-PNETs/EBTs Represented in the ACNS0334 Cohort
Time Frame: At baseline
|
The number of patients will be reported for this analysis by Molecular Sub-types of MB, CNS-PNETs/EBTs
|
At baseline
|
Percentage of Participants With Event Free Survival (EFS)
Time Frame: Baseline to up to 5 years
|
EFS was defined as time from enrollment to the occurrence of first event (disease progression/relapse, secondary malignancy, death from any cause) or date of last contact for patients who are event-free.
The percentage of participants with EFS and 90% confidence interval were provided.
The difference in incidence for the two treatment regimens were compared using a one-sided log-rank test with a significance level of 0.1.
|
Baseline to up to 5 years
|
Patterns of Failure
Time Frame: Baseline to up to 5 years
|
The patterns of failure for relapse/disease progression will be provided for patients treated with/without methotrexate drug in three categories, namely local, distant, and both local and distant.
The number of patients with each type of failure will be listed per arm.
The two groups will be compared to determine if the pattern of failure distribution is different between the two arms using Fisher exact test.
|
Baseline to up to 5 years
|
Percentage of Participants With Any Acute Adverse Events
Time Frame: Beginning of treatment to the end of consolidation
|
Event is defined as the first occurrence of any acute toxicity.
Estimates will be obtained using life-table methods.
Patients who have progression or recurrence of disease will be censored in this analysis.
Difference in incidence for the two treatment regimens will be compared using log-rank test.
|
Beginning of treatment to the end of consolidation
|
Number of Participants With Acute Hearing Loss and No Acute Hearing Loss
Time Frame: Beginning of treatment to the end of consolidation
|
Per protocol, hearing was assessed pretreatment and at regular specified intervals during treatment and off therapy, using DPOAE, audiogram or Brainstem Evoked Auditory.
Per CTCAE V4.0 grade 3 Hearing impaired is defined as follows; Pediatric (on a 1,2,3,4, 6 and 8 kHz audiogram): hearing loss sufficient to indicate therapeutic intervention, including hearing aids, threshold shift >20 dB at 3 kHz and above in at least one ear, additional speech-language related services as indicated.
Per CTCAE V4.0 grade 4 Hearing impaired is defined as follows; Pediatric Audiologic indication for cochlear implant and additional speech-language related services as indicated.
|
Beginning of treatment to the end of consolidation
|
Number of Participants With Chronic Primary Hypothyroidism/Subclinical Compensatory HypothyroidismHypothyroidism/Subclinical Compensatory Hypothyroidism
Time Frame: Off-treatment up to 9 years
|
Thyroid function was assessed as per ACNS0334 Endocrine Guidelines.
"Normal" and "Abnormal" are defined at each institution by the laboratory standards where the blood tests are run.
Primary Hypothyroidism/Subclinical Compensatory Hypothyroidism is defined as patients with Free T4 level less than "Institutional" Normal or equal to "Institutional" Normal with TSH level greater than "Institutional" Normal.
|
Off-treatment up to 9 years
|
Number of Participants With Chronic Central Hypothyroidism
Time Frame: Off-treatment up to 9 years
|
Thyroid function was assessed as per ACNS0334 Endocrine Guidelines.
"Normal" and "Abnormal" are defined at each institution by the laboratory standards where the blood tests are run.
Central Hypothyroidism is defined as Free T4 level less than "Institutional" Normal with TSH less than or equal to "Institutional" Normal.
|
Off-treatment up to 9 years
|
Number of Participants With Chronic Low Somatomedin C
Time Frame: Off-treatment up to 9 years
|
Low Somatomedin C is defined as patients with somatomedin C value less than institutional normal.
As numbers are too small, descriptive statistics such as number will be reported for this analysis.
Growth hormone function was assessed as per ACNS0334 Endocrine Guidelines.
Low Somatomedin C levels are defined at each institution by the laboratory standards where the blood tests are run.
|
Off-treatment up to 9 years
|
Number of Participants With Chronic Diabetes Insipidus
Time Frame: Beginning of off-treatment to up to 9 years
|
The number of patients who had "Diabetes Insipidus" and on DDAVP will be reported for this analysis due to small numbers..
|
Beginning of off-treatment to up to 9 years
|
Number of Participants With Secondary Malignancies
Time Frame: Off-treatment up to 9 years
|
The number of patients who had secondary malignancy will be reported for this analysis due to small numbers.
|
Off-treatment up to 9 years
|
Number of Participants With Chronic/Late Hearing Loss and No Chronic/Late Hearing Loss
Time Frame: Off-treatment up to 9 years
|
The number of patients who are reported to have abnormal hearing, graded according to CTCAE 4.0 or not, with onset while on therapy or when off therapy which persisted after off therapy will be reported and will be compared using Fisher exact test.
|
Off-treatment up to 9 years
|
Rates of Gastrointestinal Toxicities
Time Frame: Beginning of treatment to the end of consolidation
|
Rates of gastrointestinal toxicities reported as Adverse Events during therapy for each cycle will be summarized using standard descriptive methods (such as number of patients).
The difference in number of patients with gastrointestinal toxicities between the two treatment regimens will be compared using a Chi-square test.
|
Beginning of treatment to the end of consolidation
|
Rates of Nutritional Toxicities
Time Frame: Beginning of treatment to the end of consolidation
|
Rates of nutritional toxicities reported as Adverse Events during therapy for each cycle will be summarized using standard descriptive methods (such as number of patients).
The difference in number of patients with nutritional toxicities between the two treatment regimens will be compared using a Chi-square test.
|
Beginning of treatment to the end of consolidation
|
Median/Range of Patients for Total Quality of Life (QOL) Score, Intelligence Quotient (IQ) and Processing Speed Index (PSI).
Time Frame: 60 months (+/- 3 months)
|
Three tools are used to assess intelligence (IQ) depending on age. The range of IQ scores is 40-160 (mean=100, SD=15); range for the Processing Speed Index (PSI)=45-155. Higher scores represent better functioning. (1) Wechsler Preschool and Primary Scale of Intelligence-4th Edition (WPPSI-IV) is used for ages 2.5 to 6 years. Bug Search and Cancellation subtests are summed to calculate PSI. (2) Wechsler Intelligence Scales for Children-5th Edition (WISC-V) is used for ages 6 - 16 years. Symbol Search and Coding subtests are summed to calculate PSI. (3) Wechsler Adult Intelligence Scales-4th Edition (WAIS-IV) is used for ages 16 and older. Symbol Search and Coding subtests are summed to calculate PSI. The Pediatric Quality of Life Inventory Version 4 (PedsQL) measures health-related quality of life (QOL). Parents complete the measure for children ages 2-17, and patients > 18 complete a self-report version. Total scores range from 0-100, with higher scores representing better QOL. |
60 months (+/- 3 months)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Claire M Mazewski, Children's Oncology Group
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms, Glandular and Epithelial
- Glioma
- Neoplasms, Neuroepithelial
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neoplasms
- Medulloblastoma
- Neuroectodermal Tumors
- Neuroectodermal Tumors, Primitive
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Protective Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Dermatologic Agents
- Micronutrients
- Adjuvants, Immunologic
- Vitamins
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Keratolytic Agents
- Reproductive Control Agents
- Antidotes
- Vitamin B Complex
- Hematinics
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Cyclophosphamide
- Carboplatin
- Etoposide
- Etoposide phosphate
- Cisplatin
- Podophyllotoxin
- Leucovorin
- Calcium
- Levoleucovorin
- Lenograstim
- Methotrexate
- Vincristine
- Folic Acid
- Calcium, Dietary
- Thiotepa
Other Study ID Numbers
- ACNS0334 (Other Identifier: CTEP)
- U10CA180886 (U.S. NIH Grant/Contract)
- U10CA098543 (U.S. NIH Grant/Contract)
- NCI-2009-00338 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- COG-ACNS0334 (Children's Oncology Group)
- CDR0000483683
- 07-654
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Medulloblastoma
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Ependymoma | Recurrent MedulloblastomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingUntreated Childhood MedulloblastomaUnited States, Canada, Australia, New Zealand, Switzerland, Netherlands
-
University of California, San FranciscoWashington University School of Medicine; University of Washington; Pacific Pediatric... and other collaboratorsRecruitingMedulloblastoma | Medulloblastoma, Childhood | Medulloblastoma RecurrentUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood MedulloblastomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood MedulloblastomaUnited States
-
Sabine Mueller, MD, PhDMayo Clinic; Vyriad, Inc.; No More Kids With Cancer; The Matthew Larson Foundation...CompletedMedulloblastoma Recurrent | Atypical Teratoid/Rhabdoid Tumor | Medulloblastoma, Childhood, RecurrentUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingMedulloblastoma | Anaplastic MedulloblastomaUnited States, Canada, Puerto Rico, Australia, Netherlands
-
St. Jude Children's Research HospitalSt. Baldrick's FoundationCompletedMedulloblastomaUnited States
-
St. Jude Children's Research HospitalEli Lilly and CompanyActive, not recruitingBrain Cancer | Brain Tumor | Medulloblastoma | Brain Tumor, Recurrent | CNS Tumor | Medulloblastoma Recurrent | CNS Cancer | Medulloblastoma, Non-WNT/Non-SHH | Brain Tumor, Pediatric | CNS Neoplasm | Brain Tumor, Refractory | Medulloblastoma, Non-WNT/Non-SHH, Group 3 | Medulloblastoma, Non-WNT/Non-SHH, Group 4United States
-
Xinhua Hospital, Shanghai Jiao Tong University...Children's Neuro-Oncology Group (CNOG)UnknownMedulloblastoma, ChildhoodChina
Clinical Trials on Laboratory Biomarker Analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States